Attached files
| file | filename |
|---|---|
| EX-99.1 - Lineage Cell Therapeutics, Inc. | ex99-1.htm |
| EX-32 - Lineage Cell Therapeutics, Inc. | ex32.htm |
| EX-31 - Lineage Cell Therapeutics, Inc. | ex31.htm |
| EX-23.2 - Lineage Cell Therapeutics, Inc. | ex23-2.htm |
| EX-21.1 - Lineage Cell Therapeutics, Inc. | ex21-1.htm |
| EX-10.38 - Lineage Cell Therapeutics, Inc. | ex10-38.htm |
| 10-K - Lineage Cell Therapeutics, Inc. | form10-k.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-2 (Registration Nos. 333-128083 and 333-109442), Form S-3 (Registration Nos. 333-166862, 333-167822, 333-174282, 333-182964, 333-183557, 333-187710, 333-188066, 333-201824, 333-209000, 333-217182, and 333-218807), and Form S-8 (Registration Nos. 333-101651, 333-122844, 333-163396, 333-192531, 333-205661, and 333-219204) and related prospectuses of BioTime, Inc. of our reports dated March 15, 2018, with respect to the consolidated financial statements of the Company and the effectiveness of BioTime, Inc. and Subsidiaries’ internal control over financial reporting, which appear in this Annual Report on Form 10-K for the year ended December 31, 2017.
/s/ OUM & CO. LLP
San Francisco, California
March 15, 2018